Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

and health insurers who include Repatha on their formularies, but the high list price inflated co-payment costs to patients. Now, Amgen is hoping that reducing the co-pay will lead to an ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CAR-T therapy costs approximately $500,000 ... In 2015, the release of PCSK9 inhibitors like Repatha and Praluent marked another breakthrough in cholesterol treatment. These drugs, classified ...

Repatha generated revenues of $606 million ... which implies a decline from 46.9% in 2024 due to higher R&D costs. In the first quarter of 2025, Amgen expects its operating margin to be the ...

Evolucumab (Repatha) and alirocumab (Praluent ... Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

Recent launches include Repatha (cholesterol-lowering), Aimovig ... With a net margin of 6.9%, the company may face hurdles in effective cost management. Return on Equity (ROE): Amgen's financial ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...